{"id":14583,"date":"2023-05-25T18:39:16","date_gmt":"2023-05-25T22:39:16","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/?post_type=public_project&#038;p=14583"},"modified":"2026-03-11T14:36:45","modified_gmt":"2026-03-11T18:36:45","slug":"defining-the-risk-and-risk-factors-for-serotonin-syndrome-associated-with-linezolid-use-a-retrospective-cohort-study","status":"publish","type":"public_project","link":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/defining-the-risk-and-risk-factors-for-serotonin-syndrome-associated-with-linezolid-use-a-retrospective-cohort-study\/","title":{"rendered":"Defining the risk and risk factors for serotonin syndrome associated with linezolid use: a retrospective cohort study"},"content":{"rendered":"\n<p><strong>Project ID:<\/strong> 2021-925 \/ TRIM 2023 0970 304 000<br><\/p>\n\n\n\n<p><strong><strong><strong>Principal Investigator<\/strong><\/strong>:<\/strong> Anthony Bai<br><\/p>\n\n\n\n<p><strong>Description:<\/strong> Linezolid is a relatively new antibiotic approved by Canada in 2001. It is a synthetic oxazolidinone that has excellent activity against resistant gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Its bioavailability approaches 100%, making it ideal as step-down oral antibiotic therapy for bacteremia, pneumonia as well as skin and soft tissue infections. However, its use has been limited due to potential drug interactions. Linezolid can reversibly inhibit monoamine oxidase (MAO). Co-administration with anti-depressants such as non-selective MAO inhibitors, selective serotonin re-uptake inhibitors (SSRI), serotonin\u2013norepinephrine reuptake inhibitor (SNRI) and bupropion can precipitate serotonin syndrome. Anti-depressants are commonly prescribed for patients, so many patients who needed linezolid for an infection could not receive it due to this relative contraindication. However, the data on the risk of serotonin syndrome associated with linezolid has been scarce.<br><\/p>\n\n\n\n<p><strong>PIA Approved:<\/strong> April 5, 2022<\/p>\n\n\n\n<p><strong>Status:<\/strong> Completed<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Project ID: 2021-925 \/ TRIM 2023 0970 304 000 Principal Investigator: Anthony Bai Description: Linezolid is a relatively new antibiotic approved by Canada in 2001. It is a synthetic oxazolidinone that has excellent activity against resistant gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Its bioavailability approaches 100%, making it ideal [&hellip;]<\/p>\n","protected":false},"template":"","organization_type":[],"project_status":[105],"response_type":[],"class_list":["post-14583","public_project","type-public_project","status-publish","hentry","project_status-completed"],"acf":{"project_id":"2021-925 \/ TRIM 2023 0970 304 000","project_id_year":2022,"ices_scientist":"","principal_investigators":null,"knowledge_user":"","client":"","objectives":"","results":"","availability_of_results":"","pia_approved":null,"infographic":"","sitecore_item_id":"","sitecore_item_name":"","sitecore_field_values":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Defining the risk and risk factors for serotonin syndrome associated with linezolid use: a retrospective cohort study | ICES<\/title>\n<meta name=\"description\" content=\"Project ID: 2021-925 \/ TRIM 2023 0970 304 000 Principal Investigator: Anthony Bai Description: Linezolid is a relatively new antibiotic approved by Canada\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/defining-the-risk-and-risk-factors-for-serotonin-syndrome-associated-with-linezolid-use-a-retrospective-cohort-study\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Defining the risk and risk factors for serotonin syndrome associated with linezolid use: a retrospective cohort study | ICES\" \/>\n<meta property=\"og:description\" content=\"Project ID: 2021-925 \/ TRIM 2023 0970 304 000 Principal Investigator: Anthony Bai Description: Linezolid is a relatively new antibiotic approved by Canada\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/defining-the-risk-and-risk-factors-for-serotonin-syndrome-associated-with-linezolid-use-a-retrospective-cohort-study\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-11T18:36:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/public-sector-projects\\\/defining-the-risk-and-risk-factors-for-serotonin-syndrome-associated-with-linezolid-use-a-retrospective-cohort-study\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/public-sector-projects\\\/defining-the-risk-and-risk-factors-for-serotonin-syndrome-associated-with-linezolid-use-a-retrospective-cohort-study\\\/\",\"name\":\"Defining the risk and risk factors for serotonin syndrome associated with linezolid use: a retrospective cohort study | ICES\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2023-05-25T22:39:16+00:00\",\"dateModified\":\"2026-03-11T18:36:45+00:00\",\"description\":\"Project ID: 2021-925 \\\/ TRIM 2023 0970 304 000 Principal Investigator: Anthony Bai Description: Linezolid is a relatively new antibiotic approved by Canada\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/public-sector-projects\\\/defining-the-risk-and-risk-factors-for-serotonin-syndrome-associated-with-linezolid-use-a-retrospective-cohort-study\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/public-sector-projects\\\/defining-the-risk-and-risk-factors-for-serotonin-syndrome-associated-with-linezolid-use-a-retrospective-cohort-study\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/public-sector-projects\\\/defining-the-risk-and-risk-factors-for-serotonin-syndrome-associated-with-linezolid-use-a-retrospective-cohort-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Public Sector Projects\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/public-sector-projects\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Defining the risk and risk factors for serotonin syndrome associated with linezolid use: a retrospective cohort study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Defining the risk and risk factors for serotonin syndrome associated with linezolid use: a retrospective cohort study | ICES","description":"Project ID: 2021-925 \/ TRIM 2023 0970 304 000 Principal Investigator: Anthony Bai Description: Linezolid is a relatively new antibiotic approved by Canada","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/defining-the-risk-and-risk-factors-for-serotonin-syndrome-associated-with-linezolid-use-a-retrospective-cohort-study\/","og_locale":"fr_FR","og_type":"article","og_title":"Defining the risk and risk factors for serotonin syndrome associated with linezolid use: a retrospective cohort study | ICES","og_description":"Project ID: 2021-925 \/ TRIM 2023 0970 304 000 Principal Investigator: Anthony Bai Description: Linezolid is a relatively new antibiotic approved by Canada","og_url":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/defining-the-risk-and-risk-factors-for-serotonin-syndrome-associated-with-linezolid-use-a-retrospective-cohort-study\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2026-03-11T18:36:45+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/defining-the-risk-and-risk-factors-for-serotonin-syndrome-associated-with-linezolid-use-a-retrospective-cohort-study\/","url":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/defining-the-risk-and-risk-factors-for-serotonin-syndrome-associated-with-linezolid-use-a-retrospective-cohort-study\/","name":"Defining the risk and risk factors for serotonin syndrome associated with linezolid use: a retrospective cohort study | ICES","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2023-05-25T22:39:16+00:00","dateModified":"2026-03-11T18:36:45+00:00","description":"Project ID: 2021-925 \/ TRIM 2023 0970 304 000 Principal Investigator: Anthony Bai Description: Linezolid is a relatively new antibiotic approved by Canada","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/defining-the-risk-and-risk-factors-for-serotonin-syndrome-associated-with-linezolid-use-a-retrospective-cohort-study\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/defining-the-risk-and-risk-factors-for-serotonin-syndrome-associated-with-linezolid-use-a-retrospective-cohort-study\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/defining-the-risk-and-risk-factors-for-serotonin-syndrome-associated-with-linezolid-use-a-retrospective-cohort-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Public Sector Projects","item":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/"},{"@type":"ListItem","position":3,"name":"Defining the risk and risk factors for serotonin syndrome associated with linezolid use: a retrospective cohort study"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/public_project\/14583","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/public_project"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/public_project"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=14583"}],"wp:term":[{"taxonomy":"organization_type","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/organization_type?post=14583"},{"taxonomy":"project_status","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/project_status?post=14583"},{"taxonomy":"response_type","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/response_type?post=14583"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}